Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses how route of administration impacts patient adherence to inflammatory bowel disease (IBD) therapy.
Transcript
So I think everybody is different, and everybody has different priorities and thoughts on dosing and routes of administration. And so, some people are scared of giving themselves injections, for example. That certainly plays into whether or not I may recommend the utilization of a subcutaneous injection-based therapy.
In some patients, you know, logistics coming in for an infusion are challenging. And even if it is every 8 weeks or a shorter potential timeframe, that poses potential travel, caregiving from family members, as well as lost opportunity at work or school.
And so I think everybody is different in how they prioritize those. I'd say there's some pros and cons to each of those from a provider perspective. For example, with infusions, I can see if a patient is getting their infusions on time and making sure that they're administering and receiving them appropriately. Whereas with subcutaneous I have to trust that patient is administering that medication on time. And so there are nuances to each of these considerations.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Meta-Analysis Confirms Similar Safety, Efficacy Between Adalimumab Biosimilars, Humira
April 6th 2024A systematic review and meta-analysis of 7 randomized controlled trials found no significant differences in efficacy and safety indicators between adalimumab biosimilars and the reference product (Humira) for treatment of moderate to severe psoriasis.